2.30

0.86% -0.02

Aileron Therapeutics Inc (ALRN)

Overview News Price History Financials Discussions Forecast Stock Split

Aileron Therapeutics Inc stock is traded at $2.30, with a volume of 29,719. It is down -0.86% in the last 24 hours and down -19.58% over the past month. Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.

Previous Close:

$2.32

Open:

$2.34

24h Volume:

29,719

Relative Volume:

0.32

Market Cap:

$49.83M

Revenue:

Net Income/Loss:

$-12.94M

P/E Ratio:

-0.8099

EPS:

-2.84

Net Cash Flow:

$-13.83M

1W Performance:

+5.99%

1M Performance:

-19.58%

6M Performance:

-16.97%

1Y Performance:

-24.56%

1-Day Range:

$2.25

$2.35

1-Week Range:

$2.01

$2.35

52-Week Range:

$1.61

$7.42

Aileron Therapeutics Inc Stock (ALRN) Company Profile

Name

Aileron Therapeutics Inc

Sector

Healthcare (1173)

Industry

Biotechnology (670)

Phone

(737) 802-1989

Address

12407 N. MOPAC EXPY., AUSTIN, MA

Employee

Twitter

@Aileron_org

Next Earnings Date

2024-11-18

Latest SEC Filings

ALRN's Discussions on Twitter

Compare ALRN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALRN Aileron Therapeutics Inc	2.30	49.83M	0	-12.94M	-13.83M	-2.84
VRTX Vertex Pharmaceuticals Inc	402.70	103.71B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	712.33	78.28B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	615.00	36.77B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	235.31	30.35B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.95	27.32B	3.30B	-501.07M	1.03B	-2.1146

Aileron Therapeutics Inc Stock (ALRN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-24-17	Initiated	BofA/Merrill	Buy
Jul-24-17	Initiated	Jefferies	Buy
Jul-24-17	Initiated	William Blair	Outperform

Aileron Therapeutics Inc Stock (ALRN) Latest News

Dec 12, 2024

Aileron Therapeutics to Present at the 8th Annual IPF Summit - The Eastern Progress Online

Dec 12, 2024

Dec 10, 2024

Aileron Therapeutics CEO James Brian Windsor buys $897 in stock By Investing.com - Investing.com Nigeria

Dec 10, 2024

Dec 09, 2024

Aileron Therapeutics CEO James Brian Windsor buys $897 in stock - Investing.com

Dec 09, 2024

Dec 06, 2024

Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - The Eastern Progress Online

Dec 06, 2024

Nov 30, 2024

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Decrease in Short Interest - MarketBeat

Nov 30, 2024

Nov 22, 2024

Chemotherapy Induced Anemia Treatment Market 2032: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - Barchart

Nov 22, 2024

Nov 20, 2024

Aileron Therapeutics Reports Q3 2024 Financial Results - MSN

Nov 20, 2024

Nov 19, 2024

Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Citizentribune

Nov 19, 2024

Nov 17, 2024

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Down 8.7% in October - MarketBeat

Nov 17, 2024

Nov 15, 2024